Recent events
Recent events tied to this brand in public sources.
Back to profile61 entries · Page 3 of 4
2020
Sanofi stops Kevzara COVID-19 clinical trials
Sanofi stopped clinical trials of Kevzara for COVID-19 after tests found adverse effects, including pneumonia and death in some patients. The company said it no longer planned further COVID-19 clinical studies of the drug.
2020
Sanofi announces planned $3.4 billion acquisition of Principia Biopharma
Sanofi announced that it would acquire U.S.-based Principia Biopharma for $3.4 billion in cash. The transaction was expected to close in the fourth quarter of 2020, and the boards of both companies had unanimously approved it.
2020
Perrigo announces acquisition of three Eastern European OTC brands
Perrigo announced that it will acquire Emolium, Iwostin and Loxon, three Eastern European OTC skincare and hair-loss treatment brands, from Sanofi. The transaction was expected to close early in the fourth quarter, subject to customary closing conditions.
2020
Kangning Jierui and Sanofi announce strategic collaboration on KN026
Kangning Jierui's wholly owned subsidiary Jiangsu Kangning Jierui and Sanofi China Investment announced a strategic collaboration involving Taxotere for HER2-positive breast cancer patients to advance clinical research on KN026. After certain clinical milestones, Sanofi may discuss an exclusive global license with Kangning Jierui.
2020
Zentiva completes acquisition of Ankleshwar manufacturing site
Zentiva Group announced that it had completed its acquisition from Sanofi of a manufacturing site in Ankleshwar, India.
2020
Sanofi completes sale of most of its Regeneron stake
Sanofi completed the sale of 13.0 million Regeneron shares and said it had sold its entire equity investment in Regeneron, excluding 400,000 shares it retained, for total gross proceeds of $11.7 billion.
2020
FDA approves Dupixent for children aged 6 to 11
The U.S. Food and Drug Administration approved Dupixent (dupilumab) for children aged 6 to 11 with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
2020
Regeneron announces pricing of Sanofi secondary share offering and planned repurchase
Regeneron announced pricing for an underwritten secondary offering of 11,831,496 shares held by Sanofi at $515 per share, and agreed to purchase 9,806,805 shares directly from Sanofi for $5 billion. The release describes the transactions; it does not establish their completion.
2020
Sanofi clarifies its position on global vaccine access
After its CEO's earlier remarks about US patients receiving priority access to doses produced in the United States angered the French government, Sanofi clarified that any Covid-19 vaccine it developed would be made available to all. The CEO said he was sorry his earlier remarks had caused a storm.
2020
Sanofi CEO pledges coronavirus vaccine access for all regions
After French backlash, Sanofi CEO Paul Hudson said it was vital that any coronavirus vaccine reach all regions and said he was sorry that his earlier remarks had caused a storm.
2020
FDA approves Sanofi’s MenQuadfi vaccine
The U.S. Food and Drug Administration approved a Biologics License Application for Sanofi’s MenQuadfi meningococcal conjugate vaccine to prevent invasive meningococcal disease in people aged 2 years and older.
2020
Sanofi and GSK agree to jointly develop a COVID-19 vaccine
Sanofi and GSK entered an agreement to jointly create a COVID-19 vaccine, with clinical trials planned for the second half of 2020 and availability targeted for the second half of 2021.
2020
FDA approves Sarclisa for multiple myeloma
The U.S. Food and Drug Administration approved Sanofi's Sarclisa, in combination with pomalidomide and dexamethasone, for adults with relapsed or refractory multiple myeloma who had received at least two prior therapies including lenalidomide and a proteasome inhibitor.
2020
Sanofi U.S. reaches $11.85 million settlement with federal government
Sanofi U.S. announced an $11.85 million settlement agreement with the federal government to resolve an investigation relating to donations made in 2015 and 2016 to an independent charity patient assistance foundation. The company stated that the settlement did not constitute an admission of guilt.
2020
Sanofi works with U.S. agency on coronavirus vaccine
Sanofi was working with a U.S. government agency to develop a vaccine against the new coronavirus. Sanofi said a candidate could be ready for clinical trials within a year.
2020
Sanofi completes acquisition of Synthorx
Sanofi completed its acquisition of Synthorx for $68 per share in cash, making Synthorx an indirect, wholly owned subsidiary of Sanofi.
2020
Sanofi faces Zantac cancer lawsuit
Deborah Haskins filed a lawsuit against Sanofi and other drugmakers, alleging that Zantac caused her esophageal cancer and that the companies knew or should have known the medication produced high quantities of NDMA in the human body. These are allegations in the lawsuit.
2019
Sanofi Taiwan agrees to recall Tritace batch U322
Sanofi Taiwan agreed to a preventive recall of the entire Tritace 10mg batch U322 after dark spots were found on some tablets and contamination was suspected. The FDA said Sanofi Taiwan would be required to recall the batch by Jan. 9.
2019
Harris County files insulin price-fixing lawsuit
Harris County sued insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with pharmaceutical benefit managers Aetna Rx, CVS Caremark, Express Scripts and OptumRx, alleging they colluded to drive up insulin prices. The county seeks to recover more than $27 million it says it has paid to the companies.
2019
FDA approves Fluzone High-Dose Quadrivalent
The U.S. Food and Drug Administration approved a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent for use in adults 65 years of age and older.